BRPI0915439B8 - composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição - Google Patents

composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição

Info

Publication number
BRPI0915439B8
BRPI0915439B8 BRPI0915439A BRPI0915439A BRPI0915439B8 BR PI0915439 B8 BRPI0915439 B8 BR PI0915439B8 BR PI0915439 A BRPI0915439 A BR PI0915439A BR PI0915439 A BRPI0915439 A BR PI0915439A BR PI0915439 B8 BRPI0915439 B8 BR PI0915439B8
Authority
BR
Brazil
Prior art keywords
active agent
composition
actinic keratosis
preparing
combination
Prior art date
Application number
BRPI0915439A
Other languages
English (en)
Inventor
Matthies Carmen
Willers Christoph
Mallwitz Henning
Treudler Klaus
Melzer Manfred
Original Assignee
Almirall Hermal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40039993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0915439(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Hermal Gmbh filed Critical Almirall Hermal Gmbh
Publication of BRPI0915439A2 publication Critical patent/BRPI0915439A2/pt
Publication of BRPI0915439B1 publication Critical patent/BRPI0915439B1/pt
Publication of BRPI0915439B8 publication Critical patent/BRPI0915439B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição tópica para o tratamento de ceratose actínica. a presente invenção refere-se a uma composição de gel tópica compreendendo (a) um agente ativo para tratamento de ceratose actínica, (b) um agente ceratoliticamente ativo, (c) um formador de gel e (d) um solvente orgânico para uso no tratamento de ceratose actínica.
BRPI0915439A 2008-07-07 2009-06-29 composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição BRPI0915439B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08012237.7 2008-07-07
EP08012237A EP2143421A1 (en) 2008-07-07 2008-07-07 Topical composition for the treatment of actinic keratosis
PCT/EP2009/004682 WO2010003568A1 (en) 2008-07-07 2009-06-29 Topical composition for the treatment of actinic keratosis

Publications (3)

Publication Number Publication Date
BRPI0915439A2 BRPI0915439A2 (pt) 2015-11-10
BRPI0915439B1 BRPI0915439B1 (pt) 2019-10-08
BRPI0915439B8 true BRPI0915439B8 (pt) 2021-05-25

Family

ID=40039993

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915439A BRPI0915439B8 (pt) 2008-07-07 2009-06-29 composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição

Country Status (31)

Country Link
US (1) US8569320B2 (pt)
EP (2) EP2143421A1 (pt)
JP (2) JP5654987B2 (pt)
KR (1) KR101689898B1 (pt)
CN (2) CN102088957A (pt)
AR (1) AR072685A1 (pt)
AU (1) AU2009267471B2 (pt)
BR (1) BRPI0915439B8 (pt)
CA (1) CA2729974A1 (pt)
CL (1) CL2010001642A1 (pt)
CO (1) CO6351710A2 (pt)
CY (1) CY1116111T1 (pt)
DK (1) DK2315581T3 (pt)
EA (1) EA019533B1 (pt)
EC (1) ECSP11010762A (pt)
ES (1) ES2532948T3 (pt)
HR (1) HRP20150222T1 (pt)
IL (1) IL210134A (pt)
ME (1) ME02147B (pt)
MX (1) MX2011000054A (pt)
MY (1) MY158428A (pt)
NZ (1) NZ590288A (pt)
PE (1) PE20110330A1 (pt)
PL (1) PL2315581T3 (pt)
PT (1) PT2315581E (pt)
RS (1) RS53887B1 (pt)
SI (1) SI2315581T1 (pt)
TW (1) TWI433692B (pt)
UA (1) UA101044C2 (pt)
WO (1) WO2010003568A1 (pt)
ZA (1) ZA201100653B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883767B2 (en) * 2009-10-08 2014-11-11 Msd Consumer Care, Inc. Low ether compositions and delivery apparatus
JP5950528B2 (ja) * 2011-09-30 2016-07-13 小林製薬株式会社 皮膜形成性外用製剤
EP2790670A1 (en) * 2011-12-12 2014-10-22 Leo Laboratories Limited Gel compositions
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
MA40447A (fr) * 2014-07-31 2016-02-04 Sun Pharmaceutical Ind Ltd Composition pharmaceutique orale d'isotrétinoïne
EP3967312A1 (en) 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
AU2015402192B2 (en) * 2015-07-10 2021-06-10 Infectopharm Arzneimittel Und Consilium Gmbh Use of potassium hydroxide in the treatment of actinic keratosis
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
WO2018165647A1 (en) 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
US20220175769A1 (en) * 2020-12-08 2022-06-09 Ankh Life Sciences Limited Method of treatment of actinic keratoses
DK202370132A1 (en) * 2023-03-14 2024-10-10 Repoceuticals Aps Compositions for use in the treatment of actinic keratosis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
JP3117502B2 (ja) * 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
US5627187A (en) * 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
RU2197273C2 (ru) * 1996-06-20 2003-01-27 Лавифарм С.А. Приспособление в виде пластыря для местного нанесения противоугревого состава и способ его изготовления
US5993787A (en) * 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
US5955097A (en) * 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6462071B1 (en) * 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
ES2223277B1 (es) * 2003-06-19 2006-03-01 Fernando Bouffard Fita Composicion anestesica para administracion topica.
EP1663148A2 (en) * 2003-08-25 2006-06-07 Foamix Ltd. Penetrating pharmaceutical foam
WO2005027977A2 (en) * 2003-09-22 2005-03-31 Agis Industries (1983) Ltd. Diclofenac compositions for the treatment of skin disorders
AU2005267396B2 (en) * 2004-06-24 2009-09-17 Idexx Laboratories, Inc. Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
US20070053984A1 (en) 2005-03-03 2007-03-08 Monique Spann-Wade Topical gels compositions
WO2006134406A1 (en) * 2005-06-14 2006-12-21 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical gel of diclofenac sodium
US7851431B2 (en) * 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
WO2008047857A1 (fr) * 2006-10-18 2008-04-24 Fujifilm Corporation Procédé de production d'une composition comprenant un composé difficilement soluble dans l'eau incorporé dans une matrice hydrophile et préparation pour une utilisation externe comprenant un agent ou médicament anticancéreux ayant un coefficient de partage octanol/eau (log p) de -3,0 ou plus mais pas plus de 3,0, incorporé

Also Published As

Publication number Publication date
KR101689898B1 (ko) 2016-12-26
CN104825384A (zh) 2015-08-12
EP2143421A1 (en) 2010-01-13
AU2009267471B2 (en) 2014-06-05
MX2011000054A (es) 2011-11-04
CY1116111T1 (el) 2017-02-08
UA101044C2 (ru) 2013-02-25
BRPI0915439B1 (pt) 2019-10-08
PE20110330A1 (es) 2011-06-11
AU2009267471A1 (en) 2010-01-14
ES2532948T3 (es) 2015-04-06
WO2010003568A8 (en) 2011-02-03
US8569320B2 (en) 2013-10-29
CO6351710A2 (es) 2011-12-20
CL2010001642A1 (es) 2011-04-08
KR20110027838A (ko) 2011-03-16
WO2010003568A1 (en) 2010-01-14
TWI433692B (zh) 2014-04-11
NZ590288A (en) 2012-08-31
EA201100020A1 (ru) 2011-06-30
JP5654987B2 (ja) 2015-01-14
MY158428A (en) 2016-10-14
ME02147B (me) 2015-10-20
RS53887B1 (sr) 2015-08-31
IL210134A (en) 2015-06-30
AR072685A1 (es) 2010-09-15
ECSP11010762A (es) 2012-03-30
BRPI0915439A2 (pt) 2015-11-10
CA2729974A1 (en) 2010-01-14
EP2315581B1 (en) 2014-12-17
JP2011526934A (ja) 2011-10-20
DK2315581T3 (en) 2015-03-23
SI2315581T1 (sl) 2015-05-29
CN102088957A (zh) 2011-06-08
HRP20150222T1 (hr) 2015-05-22
IL210134A0 (en) 2011-02-28
ZA201100653B (en) 2011-10-26
PL2315581T3 (pl) 2015-06-30
PT2315581E (pt) 2015-04-02
EP2315581A1 (en) 2011-05-04
HK1154793A1 (en) 2012-05-04
EA019533B1 (ru) 2014-04-30
JP2015038129A (ja) 2015-02-26
TW201006507A (en) 2010-02-16
US20110301130A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
BRPI0915439B8 (pt) composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
BR112013018352A2 (pt) composição de minociclina tópica e método
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112013000537A2 (pt) composição aquosa contendo bromexina
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
CL2011000301A1 (es) Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer.
ECSP11010831A (es) Compuestos orgánicos para la cicatrización de heridas
EA202091999A3 (ru) Применение ингибиторов dpp iv
BR112012015428A2 (pt) composições de cuidado oral para uso com um dispositivo de luz oral
CO6280490A2 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
UY30364A1 (es) Arilimidazolonas y ariltriazolonas sustituidas asi como su uso
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
BRPI0924653B8 (pt) composto de ferro-oligossacarídeo, composição e uso de deste composto
ECSP10010494A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
CL2009000665A1 (es) Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
BR112013010325A2 (pt) composições para o tratamento de úlceras periféricas de várias origens
BRPI0506888A (pt) composições de suplemento lìquido compreendendo um ou mais medicamentos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF